Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 20, Issue 3, Pages 349-352Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2015.1050377
Keywords
asthma; discriminatory biomarkers; IL-13; IL-4
Categories
Ask authors/readers for more resources
It is recognised that airway inflammation is key to asthma pathogenesis. Biopharmaceutical approaches have identified new therapies that target key cells and mediators that drive the inflammatory responses in the asthmatic lung. Such an approach resulted in the development of biologics targeted at inhibition of IL-4, IL-5 and IL-13. However, early clinical trials with these biologics in patients with asthma were for the most par disappointing even though they were highly effective in animal models of asthma. It is becoming apparent that significant clinical effects with anti-cytokine-based biologic therapies are more likely in carefully selected patient populations that take asthma phenotypes into account. The development of discriminatory biomarkers and genetic profiling may aid identification of such patients with asthma. This review is an update of the evidence demonstrating the effectiveness or otherwise of the targeting of the T(H)2 cytokines IL-4 and IL-13 with biologics in patients with asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available